MG
RPRX icon

Mather Group’s Royalty Pharma RPRX Stock Holding History

Mather Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42K Sell
25
-22
-47% -$1.15K ﹤0.01% 1771
2026
Q1 		$2.27K Buy
+47
New +$2.06K ﹤0.01% 1687
2025
Q4 		– Sell
-8
Closed -$290 – 1444
2025
Q3 		$290 Buy
+8
New +$290 ﹤0.01% 1657
2025
Q2 		– Sell
-80
Closed -$2.49K – 1490
2025
Q1 		$2.49K Buy
+80
New +$2.54K ﹤0.01% 1540
2024
Q4 		– Sell
-107
Closed -$3.04K – 1772
2024
Q3 		$3.04K Buy
107
+91
+569% +$2.52K ﹤0.01% 1400
2024
Q2 		$494 Sell
16
-10
-38% -$277 ﹤0.01% 2073
2024
Q1 		$737 Buy
+26
New +$766 ﹤0.01% 1658

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mather Group's RPRX Position: Q2 2026 in Review

Mather Group reduced its Royalty Pharma (RPRX) stake by 47% in Q2 2026, selling an estimated $1.15K and leaving 25 shares worth $1.42K. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

Mather Group first reported a position in RPRX in Q1 2024 and has held it in 7 quarters since. The position peaked at $3.04K in Q3 2024. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Mather Group held 25 shares of Royalty Pharma worth $1.42K as of Q2 2026.
  • Mather Group sold 22 Royalty Pharma shares in Q2 2026, an estimated $1.15K.
  • Royalty Pharma made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1771 holding.
  • Mather Group first reported a position in Royalty Pharma in Q1 2024 and has held it in 7 quarters since.
  • Mather Group's Royalty Pharma position peaked at $3.04K in Q3 2024.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.